Human Erythropoietin Injection

A clinical first-line drug and an industry-leading product for the treatment of anemia in many fields

EPOSINO is the first batch of human erythropoietin approved for R&D in China and obtained the New Drug Certificate and NMPA's official approval number. It is complete in dosage forms and strengths and firstly administrated by pre-filled syringes for more convenient clinical drug selection. As an industry-leading product, it has been accessed into and sold in more than 30 countries, including Brazil, the Philippines and Indonesia.

Indications

EPOSINO is used to treat anemia resulting from renal function insufficiency, including hemodialysis and non-hemodialysis. 

EPOSINO is used to treat red blood cell mobilization during surgical perioperative period. 

EPOSINO is used to treat anemia caused by chemotherapy in patients with non bone marrow malignancies. Only when the hemoglobin level is below 100g/L and the patient is expected to have at least two months of chemotherapy plan, should treatment with this product be initiated.

Strength

2000IU/ml/vial (PFS)

4000IU/ml/vial (PFS) 

6000IU/ml/vial (PFS)

10000IU/ml/vial (PFS) 

The Benefits and Risks of Human Erythropoietin Injection: What You Need to Know

The Importance of Choosing a Reliable Human Erythropoietin Injection Manufacturer